- Home
- D vs ALNY Comparison
D vs ALNY Comparison
Compare D & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- D
- ALNY
- Stock Information
- Founded
- D 1983
- ALNY 2002
- Country
- D United States
- ALNY United States
- Employees
- D N/A
- ALNY N/A
- Industry
- D
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- D
- ALNY Health Care
- Exchange
- D Nasdaq
- ALNY Nasdaq
- Market Cap
- D 51.5B
- ALNY 59.6B
- IPO Year
- D N/A
- ALNY 2004
- Fundamental
- Price
- D $59.75
- ALNY $452.17
- Analyst Decision
- D Hold
- ALNY Strong Buy
- Analyst Count
- D 7
- ALNY 29
- Target Price
- D $59.57
- ALNY $435.04
- AVG Volume (30 Days)
- D 4.9M
- ALNY 1.1M
- Earning Date
- D 10-31-2025
- ALNY 10-30-2025
- Dividend Yield
- D 4.46%
- ALNY N/A
- EPS Growth
- D 86.34
- ALNY N/A
- EPS
- D 2.99
- ALNY N/A
- Revenue
- D $15,227,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- D $11.04
- ALNY $58.79
- Revenue Next Year
- D $6.20
- ALNY $39.75
- P/E Ratio
- D $20.04
- ALNY N/A
- Revenue Growth
- D 5.29
- ALNY 5.01
- 52 Week Low
- D $48.07
- ALNY $205.87
- 52 Week High
- D $62.46
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- D 50.61
- ALNY 54.93
- Support Level
- D $59.36
- ALNY $454.51
- Resistance Level
- D $60.75
- ALNY $467.28
- Average True Range (ATR)
- D 0.94
- ALNY 12.99
- MACD
- D 0.01
- ALNY -4.32
- Stochastic Oscillator
- D 68.65
- ALNY 24.98
About D Dominion Energy Inc.
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.